IN2012DN03448A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN03448A IN2012DN03448A IN3448DEN2012A IN2012DN03448A IN 2012DN03448 A IN2012DN03448 A IN 2012DN03448A IN 3448DEN2012 A IN3448DEN2012 A IN 3448DEN2012A IN 2012DN03448 A IN2012DN03448 A IN 2012DN03448A
- Authority
- IN
- India
- Prior art keywords
- compounds
- methods
- administration
- preparing
- disclosed
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229940122361 Bisphosphonate Drugs 0.000 abstract 1
- 208000018083 Bone metabolism disease Diseases 0.000 abstract 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 abstract 1
- -1 bisphosphonate cyclic acetal compounds Chemical class 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
- C07F9/65746—Esters of oxyacids of phosphorus the molecule containing more than one cyclic phosphorus atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
- C07F9/657181—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25488609P | 2009-10-26 | 2009-10-26 | |
| PCT/US2010/054124 WO2011056589A1 (fr) | 2009-10-26 | 2010-10-26 | Composés bisphosphonates destinés au traitement de troubles du métabolisme osseux |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN03448A true IN2012DN03448A (fr) | 2015-10-23 |
Family
ID=43478185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3448DEN2012 IN2012DN03448A (fr) | 2009-10-26 | 2010-10-26 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US8314081B2 (fr) |
| EP (1) | EP2493905B1 (fr) |
| JP (1) | JP5850842B2 (fr) |
| CN (1) | CN102630227B (fr) |
| CA (1) | CA2778015C (fr) |
| IL (1) | IL219235A (fr) |
| IN (1) | IN2012DN03448A (fr) |
| MX (1) | MX2012004769A (fr) |
| SG (1) | SG10201406846XA (fr) |
| WO (1) | WO2011056589A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2778015C (fr) | 2009-10-26 | 2016-08-02 | Warner Chilcott Company, Llc | Composes bisphosphonates destines au traitement de troubles du metabolisme osseux |
| US11974971B2 (en) | 2011-01-07 | 2024-05-07 | Anji Pharmaceuticals Inc. | Compositions and methods for treating metabolic disorders |
| KR20200137035A (ko) * | 2012-01-06 | 2020-12-08 | 앤지 파마 유에스 엘엘씨 | 바이구아나이드 조성물 및 대사 장애를 치료하는 방법 |
| EP3623364A1 (fr) * | 2014-02-13 | 2020-03-18 | Ligand Pharmaceuticals, Inc. | Composés de promédicaments et leurs utilisations |
| CN106687118A (zh) * | 2014-07-02 | 2017-05-17 | 配体药物公司 | 前药化合物及其用途 |
| JP2021509907A (ja) | 2018-01-09 | 2021-04-08 | リガンド・ファーマシューティカルズ・インコーポレイテッド | アセタール化合物およびその治療的使用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2043072B (en) * | 1979-02-13 | 1983-11-23 | Symphar Sa | Diphosphonate compounds |
| DE3640938A1 (de) * | 1986-11-29 | 1988-06-01 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindung enthaltende arzneimittel |
| US4990503A (en) * | 1988-08-12 | 1991-02-05 | Yamanouchi Pharmaceutical Co., Ltd. | Heterocyclic bisphosphonic acid derivatives |
| JPH0699457B2 (ja) * | 1988-08-12 | 1994-12-07 | 山之内製薬株式会社 | ヘテロ環ビスフォスフォン酸誘導体およびその医薬 |
| US5039699A (en) * | 1989-03-27 | 1991-08-13 | Lederle (Japan), Ltd. | Anti-peptic ulcer agent |
| US5227506A (en) * | 1989-09-06 | 1993-07-13 | Merck & Co., Inc. | Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors |
| FI89366C (fi) * | 1990-12-20 | 1993-09-27 | Leiras Oy | Foerfarande foer framstaellning av nya farmakologiskt anvaendbara metylenbisfosfonsyraderivat |
| US5157027A (en) | 1991-05-13 | 1992-10-20 | E. R. Squibb & Sons, Inc. | Bisphosphonate squalene synthetase inhibitors and method |
| DE69224830D1 (en) | 1991-06-19 | 1998-04-23 | Upjohn Co | Dialkyl (dialkoxyphosphinyl)methyl phosphate als antientzündungsmittel |
| JPH05239075A (ja) * | 1991-08-27 | 1993-09-17 | Eisai Co Ltd | 含リンイソプレノイド誘導体 |
| EP0541037A3 (en) * | 1991-11-06 | 1997-02-26 | Takeda Chemical Industries Ltd | Squalene synthetase inhibitory composition and use thereof |
| JPH06172372A (ja) * | 1991-11-06 | 1994-06-21 | Takeda Chem Ind Ltd | スクアレン合成酵素阻害剤およびその用途 |
| US5366965A (en) * | 1993-01-29 | 1994-11-22 | Boehringer Mannheim Gmbh | Regimen for treatment or prophylaxis of osteoporosis |
| JP3526575B2 (ja) * | 1993-03-08 | 2004-05-17 | エーザイ株式会社 | ホスホン酸誘導体 |
| US5510517A (en) * | 1993-08-25 | 1996-04-23 | Merck & Co., Inc. | Process for producing N-amino-1-hydroxy-alkylidene-1,1-bisphosphonic acids |
| EP0705834A1 (fr) | 1994-07-27 | 1996-04-10 | Ciba-Geigy Ag | Quinoxaline-2,3-diones à anneau fusionné azahétérocyclique |
| US7645459B2 (en) * | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of bisphosphonates |
| US7645460B2 (en) * | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of risedronate |
| WO2008128056A1 (fr) * | 2004-10-08 | 2008-10-23 | The Board Of Trustees Of The University Of Illinois | Composés bisphosphonates et procédés présentant un potentiel amélioré pour cibles multiples incluant fpps, ggpps, et dpps |
| US7358361B2 (en) * | 2004-10-08 | 2008-04-15 | The Board Of Trustees Of The University Of Illinois | Biophosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases |
| US7781418B2 (en) | 2006-12-14 | 2010-08-24 | Isis Innovation Ltd. | Composition for treating bone disorders |
| US8252774B2 (en) | 2008-09-22 | 2012-08-28 | Isis Innovation Ltd. | 5-azaindole bisphosphonates |
| US8618079B2 (en) | 2008-09-22 | 2013-12-31 | Isis Innovation Limited | Imidazo[1,2-a] pyridinyl bisphosphonates |
| WO2010033980A2 (fr) | 2008-09-22 | 2010-03-25 | Isis Innovation Ltd. | 4-azaindole bisphosphonates |
| CA2778015C (fr) | 2009-10-26 | 2016-08-02 | Warner Chilcott Company, Llc | Composes bisphosphonates destines au traitement de troubles du metabolisme osseux |
-
2010
- 2010-10-26 CA CA2778015A patent/CA2778015C/fr active Active
- 2010-10-26 JP JP2012536961A patent/JP5850842B2/ja active Active
- 2010-10-26 CN CN201080054060.1A patent/CN102630227B/zh active Active
- 2010-10-26 IN IN3448DEN2012 patent/IN2012DN03448A/en unknown
- 2010-10-26 US US12/912,514 patent/US8314081B2/en active Active
- 2010-10-26 EP EP10773501.1A patent/EP2493905B1/fr not_active Not-in-force
- 2010-10-26 MX MX2012004769A patent/MX2012004769A/es active IP Right Grant
- 2010-10-26 WO PCT/US2010/054124 patent/WO2011056589A1/fr active Application Filing
- 2010-10-26 SG SG10201406846XA patent/SG10201406846XA/en unknown
-
2012
- 2012-04-17 IL IL219235A patent/IL219235A/en active IP Right Grant
- 2012-10-12 US US13/650,785 patent/US8710215B2/en active Active
-
2014
- 2014-03-12 US US14/205,937 patent/US8822435B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011056589A1 (fr) | 2011-05-12 |
| MX2012004769A (es) | 2012-08-08 |
| CA2778015A1 (fr) | 2011-05-12 |
| CA2778015C (fr) | 2016-08-02 |
| US20130035482A1 (en) | 2013-02-07 |
| SG10201406846XA (en) | 2014-12-30 |
| CN102630227B (zh) | 2016-03-23 |
| US8822435B2 (en) | 2014-09-02 |
| US8710215B2 (en) | 2014-04-29 |
| JP5850842B2 (ja) | 2016-02-03 |
| US20140194389A1 (en) | 2014-07-10 |
| EP2493905A1 (fr) | 2012-09-05 |
| US20110098251A1 (en) | 2011-04-28 |
| CN102630227A (zh) | 2012-08-08 |
| IL219235A (en) | 2017-01-31 |
| IL219235A0 (en) | 2012-06-28 |
| JP2013508459A (ja) | 2013-03-07 |
| EP2493905B1 (fr) | 2016-11-30 |
| US8314081B2 (en) | 2012-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN09805A (fr) | ||
| TN2012000126A1 (en) | Polycyclic compounds as lysophosphatidic acid receptor antagonists | |
| IN2012DN02177A (fr) | ||
| IN2012DN00754A (fr) | ||
| IN2014DN09804A (fr) | ||
| EA201290482A1 (ru) | Стабильные составы для лиофилизации терапевтических частиц | |
| WO2009135190A3 (fr) | Particules de phosphate de calcium thérapeutiques et procédés pour les fabriquer et les utiliser | |
| MX2011007930A (es) | Conjugados de insulina cristalina. | |
| MX2013006040A (es) | Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis. | |
| MX2013011908A (es) | Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank. | |
| MX343135B (es) | Compuestos de tipo fumagilol y métodos de realización y uso de los mismos. | |
| MY155564A (en) | Arginine salts and their uses for the treatment of illnesses in the oral cavity | |
| MX2019000547A (es) | Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas. | |
| IN2012DN03448A (fr) | ||
| MX2012004078A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119. | |
| MY156302A (en) | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ß-AMYLOID DISEASES AND SYNUCLEINOPATHIES | |
| MX2011013032A (es) | Inhibidores de fosfatidilinositol 3-cinasa. | |
| MX2019012939A (es) | Formulaciones que contienen linaclotida para administracion oral. | |
| MX360554B (es) | Composiciones que comprenden y metodos que utilizan inhibidores de co-transportadores de glucosa-sodio 1 y 2. | |
| WO2011023367A3 (fr) | Promédicaments bisphosphonates | |
| BR112012026098A2 (pt) | métodos e composições para melhorar a osseointegração de implante. | |
| PH12015500111A1 (en) | Difluorolactam compositions for ep4-mediated osteo related diseases and conditions | |
| MX2013013649A (es) | Compuestos de quinona para tratar enfermedades mediadas por ape1. | |
| MX342119B (es) | 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3. | |
| MX2009011577A (es) | Composiciones y metodos para distribucion de domperidona a traves de la mucosa. |